Luspatercept to improve blood cell recovery after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called luspatercept to see if it can help your body make blood cells faster after a stem cell transplant. It is for people with blood cancers and moderate to severe bone marrow scarring (myelofibrosis).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a blood cancer with moderate to severe bone marrow scarring (myelofibrosis).
- You are planning to have your first stem cell transplant from a donor (allogeneic transplant).
- Your cancer is in remission (no signs of active disease) before the transplant.
- You are generally able to care for yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.